Patel Chem Specialities Ltd H1 FY26 – ₹61 Cr Revenue, 38% Profit CAGR, ROE 38% and a Capacity Bombshell from 3,720 to 9,732 MTPA
1. At a Glance – Chemicals, Cellulose & Cash Discipline (With a Side of Swagger)
Patel Chem Specialities Ltd is what happens when a boring-sounding cellulose business quietly walks into the SME market and starts flexing numbers like it’s auditioning for a specialty chemical version of Shark Tank. Listed at ₹81 with a market cap of roughly ₹201 crore, this company has managed to clock H1 FY26 revenue of ₹61.16 crore and PAT of ₹6.13 crore, while the stock itself has corrected ~26.5% over the last three months like an obedient midcap during mood swings. ROE is sitting at a spicy 38.5%, ROCE at 35.2%, debt-to-equity at a very polite 0.22, and P/E around 17.6 – which in specialty chemicals land is almost suspiciously reasonable. The business isn’t flashy, doesn’t promise “AI-powered molecules”, but quietly sells stuff that tablets, cosmetics, food and industrial users literally cannot function without. The cherry on top? A greenfield expansion that will more than double capacity by March 2026. So the obvious question – is this a boring compounder hiding in plain sight, or just another SME IPO honeymoon story waiting to cool off?
2. Introduction – From Cellulose to Cash Flow, No Bollywood Drama Required
Patel Chem Specialities Limited was incorporated in 2008, long before specialty chemicals became the favourite buzzword of every investor presentation in India. Back then, “cellulose-based excipients” didn’t sound sexy; today, they are mission-critical ingredients across pharmaceuticals, cosmetics, food, beverages, and industrial applications. PCSL manufactures excipients that act as binders, disintegrants, thickeners, stabilizers, and gelling agents – basically the backstage crew of finished products. Nobody claps for them, but the show collapses without them.
The company raised about ₹55.8 crore through its IPO and got listed on August 1, 2025. Since then, it has reported steady growth, healthy margins, and a balance sheet that doesn’t scream “stress”. Revenue has grown at a 3-year CAGR of ~20%, while profits have compounded at a hilarious 67% CAGR over the same period. For a company doing just over ₹100 crore in annual sales, those numbers are not small talk.
Yet, this is not a fairy tale. It’s an SME-listed company, operating in a competitive chemicals space, with working capital needs, expansion execution risk, and a heavy tilt towards cosmetics and food rather than pharma. So before we get carried away, let’s dissect this business like a pharmacist reads a medicine label – slowly, carefully, and with suspicion.
3. Business Model – WTF Do They Even Do?
Patel Chem makes cellulose-based excipients. Translation for lazy investors: they take cellulose (plant-based raw material) and chemically process it into functional ingredients that make tablets dissolve properly, cosmetics feel smooth, sauces stay thick, and industrial formulations behave nicely.
Their product portfolio includes:
Rheollose (Sodium CMC) – thickener and stabilizer.
Disolwell (Croscarmellose Sodium) – super disintegrant in pharma tablets.
Swellcal (Calcium CMC) – another pharma-focused disintegrant.
AmyloTab (Pregelatinized Starch) – tablet disintegration and dissolution aid.
Current installed capacity stands at 3,720 MTPA, with utilisation hovering between ~80–88% depending on the unit. Demand clearly isn’t the problem, which is why management is going full desi expansion mode with a greenfield plant at Indrad, Mehsana, adding 6,012 MTPA and taking total capacity to 9,732 MTPA by March 2026.
Clients? Over 350 globally, with no single customer contributing more than 7% of revenue. Geography is still India-heavy at 84%, exports at 16%. If this was a Bollywood movie, exports are still in a “supporting role”, not the hero yet.
Now ask yourself – is this a scalable specialty chemicals platform, or just a well-run niche supplier? Keep reading.
4. Financials Overview – Half-Yearly Results, No Confusion Allowed
Result Type Locked: HALF-YEARLY RESULTS EPS annualisation rule applied: Annualised EPS = Latest EPS × 2
H1 FY26 Financial Comparison Table (₹ Crore)
Source table
Metric
Latest H1 FY26
H1 FY25
H2 FY25
YoY %
HoH %
Revenue
61
50
55
22.0%
10.9%
EBITDA
8
8
8
~0%
~0%
PAT
6
5
5
17.4%
20.0%
EPS (₹)
2.46
2.99
–
-17.7%
–
Annualised EPS (₹): 2.46 × 2 = ₹4.92
Witty commentary: Revenue is growing, profits are growing, margins are holding, but EPS looks slightly weird due to equity expansion post-IPO. This is not earnings collapse; this is denominator gymnastics. Anyone panicking at EPS without reading balance sheet changes deserves a timeout.
